Kevin M. Flanigan
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
373
Citations
16,217
Est. group size
~5
Recurring co-author estimate
Active years
34
Publishing since 1993
Kevin M. Flanigan's research focuses on genetic neuromuscular and neurodevelopmental disorders, particularly Duchenne muscular dystrophy (a genetic muscle-wasting disease) and mucopolysaccharidosis (a rare inherited metabolic disorder affecting the brain and body). Much of his work involves clinical trials testing gene therapies, exon-skipping drugs (treatments that help cells skip over faulty genetic instructions), and biomarkers to monitor disease progression and treatment response. His publications frequently report results from multicenter clinical trials evaluating new gene therapy products in children.
Publication output has remained relatively steady over the last decade, with modest year-to-year fluctuations and no clear long-term increase or decline.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Treatment with UX111 reduced cerebrospinal fluid (CSF) heparan sulfate (HS) exposure and stabilized or improved functioning across dose, age, and stage of MPS IIIA
Molecular Genetics and Metabolism · 2026
- Treatment with UX111 (rebisufligene etisparvovec) led to sustained reductions in cerebrospinal fluid (CSF) heparan sulfate (HS) exposure and stabilized or improved functioning across dose, age, and stage of MPS IIIA
Molecular Genetics and Metabolism · 2026
- Neurobehavioral Profiles in Young Steroid-Naive Boys With Duchenne Muscular Dystrophy
Neurology · 2026
- Evaluation of a serum protein signature as monitoring biomarker for Duchenne muscular dystrophy in a long-term clinical trial with corticosteroids
Skeletal Muscle · 2026
- Current clinical applications of AAV-mediated gene therapy
Molecular Therapy · 2025
- Treatment with UX111 gene therapy rapidly reduced heparan sulfate (HS) exposure in cerebrospinal fluid (CSF) and improved long-term cognitive function in children with mucopolysaccharidosis type IIIA (MPS IIIA)
Molecular Genetics and Metabolism · 2025
- Treatment with UX111 Gene Therapy Rapidly Reduced Heparan Sulfate (HS) Exposure in Cerebrospinal Fluid (CSF) and Improved Long-term Cognitive Function in Children with Mucopolysaccharidosis IIIA (MPS IIIA) (S31.001)
Neurology · 2025
- Re-evaluating acceptable risk of death from gene therapy: A threshold study among individuals with Duchenne muscular dystrophy and their caregivers in the US and UK
European Journal of Medical Genetics · 2025
- Safety and Efficacy of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping (S31.010)
Neurology · 2025
- Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies – Developing Potential Treatments for the Entire Spectrum of Disease
Journal of Neuromuscular Diseases · 2024
- Interim results of Transpher A, a multicenter, single-dose clinical trial of UX111 gene therapy for Sanfilippo syndrome type A (mucopolysaccharidosis IIIA)
Molecular Genetics and Metabolism · 2023
- Updated results of Transpher A, a multicenter, single-dose, Phase 1/2 clinical trial of ABO-102 investigational gene therapy for Sanfilippo syndrome type A (mucopolysaccharidosis IIIA) (S39.008)
Neurology · 2022
- Interim results of Transpher A, a multicentre, single-dose, phase 1/2 clinical trial of ABO-102 investigational gene therapy for Sanfilippo syndrome type A (mucopolysaccharidosis IIIA)
Molecular Genetics and Metabolism · 2022
- Letter by Duan et al Regarding Article, “Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy In Vivo”
Circulation · 2022
- Update in the Mucopolysaccharidoses
Seminars in Pediatric Neurology · 2021
- Neuromuscular Disorders×35
- Molecular Genetics and Metabolism×20
- Neurology×9
- Journal of Neuromuscular Diseases×8
- Molecular Therapy×6
- Scott Q. Harper
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Afrooz Rashnonejad
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- K. Flanigan
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Stefan Nicolau
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Anne M. Connolly
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile